Assessment of Hand Funtion Pre and Post Anti-tumour Necrosis Factor-a (TNF) Therapy

Trial Profile

Assessment of Hand Funtion Pre and Post Anti-tumour Necrosis Factor-a (TNF) Therapy

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Feb 2016 Planned number of patients changed from 20 to 13 as reported by United Kingdom Clinical Research Network.
    • 25 Feb 2016 Accrual to date is 100% as reported by United Kingdom Clinical Research Network.
    • 25 Feb 2016 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top